电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Luteinizing Hormone ELISA 试剂盒

The 人 Luteinizing Hormone ELISA Kit (ABIN577071) is a Colorimetric ELISA Kit designed to quantify 人 Luteinizing Hormone.
产品编号 ABIN577071
发货至: 中国
Contact our Customer Service for availability and price in your country. Contact Info

Our Local Distributor

中国
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
4A Biotech Co.,Ltd.
Tel +86 (0512) 65829739 传真 +86 (010) 6788 5057

Quick Overview for Luteinizing Hormone ELISA 试剂盒 (ABIN577071)

抗原

See all Luteinizing Hormone (LH) ELISA试剂盒
Luteinizing Hormone (LH)

适用

  • 8
  • 7
  • 6
  • 5
  • 4
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 1
  • 1
  • 1

检测方法

Colorimetric

实验类型

Sandwich ELISA

应用范围

ELISA
  • 原理

    This LH enzyme linked immunosorbent assay (ELISA) applies a technique called a quantitative sandwich immunoassay. The microtiter plate provided in this kit has been pre- coated with a monoclonal antibody specific for LH. Standards or samples are then added to the microtiter plate wells and LH if present, will bind to the antibody pre-coated on the wells. In order to quantitate the amount of LH present in the sample, a standardized preparation of horseradish peroxidase (HRP)-conjugated polyclonal antibody, specific for LH are added to each well to

    Analytical Method

    Quantitative

    灵敏度

    The minimal detectable concentration of LH by this assay is estimated to be 3 mIU/ml.

    组件

    Standards: 1 set/2 vials
  • 板类型

    Pre-coated

    限制

    仅限研究用
  • 储存液

    Without preservative
  • 抗原 See all Luteinizing Hormone (LH) ELISA试剂盒

    Luteinizing Hormone (LH)

    物质类

    Hormone

    背景

    Prostate-Specific Antigen (PSA) is a single-chain glycoprotein weighing approximately 34 kDa1. PSA is a secretion of the prostate epithelium produced by normal, benign, and cancerous cells2. PSA is functionally and immuno-chemically distinct from Prostatic Acid Phosphatase. Development of an enzyme immunoassay3 has made it possible to accurately detect low concentrations of PSA in the blood of patients with malignant and benign prostate disease. PSA serum levels are elevated in patients with prostate cancer, benign prostatic hypertrophy (BPH) and inflammatory conditions associated with the surgical stage and metastasis of the disease. After several years of clinical use, PSA has emerged as the choice overall serum marker for prostate cancer. Furthermore, numerous investigators consider S P A to be the most useful and meaningful tumour marker in cancer biology2,4. PSA is a useful serum marker for prostate cancer and represents a valuable new tool for the clinician. When used in combination with the digital rectal exam and/or transrectal ultrasound, PSA may assist in early detection programs for prostate cancer. Additionally, costly and time-consuming bone scans can be avoided for patients with newly diagnosed and untreated prostate cancer. The latter assumes a negative bone scan and therefore, a staging bone scintigram may not be necessary. Finally, an ultra- sensitive PSA assay would be useful when monitoring patients for residual disease following radical r p ostatectomy, as well as earlier detection of recurrent active disease following such therapies
You are here: